A vaccine given during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a reduction of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and passing protection through the placenta. A major new study analysing nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the timeframe when infants are most vulnerable to the virus. RSV affects roughly 50 per cent of newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the vaccine protects vulnerable infants
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects roughly half of all newborns during their first few months of life. The virus can range from causing mild cold-like symptoms to causing severe chest infections that leave babies struggling to breathe and feed. In the most severe cases, the lung inflammation becomes life-threatening, with small numbers of babies dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of serious RSV infections: “In babies with severe infections you can see their chest and lungs working hard, as they try to pull enough oxygen in. This is extremely frightening as a parent, frightening for good reason.”
The pregnancy vaccine operates by activating the mother’s immune system to produce protective antibodies, which are then passed to the developing baby through the placenta. This maternal immunity offers newborns with immediate protection from the moment of birth, precisely when they are most vulnerable to RSV. The latest research demonstrates that protection reaches nearly 85 per cent when the vaccine is administered four weeks or more before delivery. Even briefer gaps between vaccination and birth can still deliver substantial defence, with evidence indicating that a two-week gap is sufficient to shield babies delivered prematurely. Dr Watson advises pregnant women to receive the vaccine at the recommended time, whilst observing that protection remains possible even if administered later in the third trimester.
- Nearly 85 per cent protection when vaccinated 4 weeks before birth
- Antibodies from the mother transferred through placenta protect newborns from birth
- Coverage possible with 2-week gap before premature birth
- Vaccination in third trimester still offers meaningful protection for infants
Compelling evidence from the latest research
The performance of the RSV vaccine administered during pregnancy has been confirmed through a comprehensive study conducted across England, examining data from approximately 300,000 babies born between September 2024 and March 2025. This accounts for approximately 90% of all births during that six-month period, providing robust and representative information of the vaccine’s practical effectiveness. The study’s conclusions have been validated by the UK Health Security Agency as showing robust protection for newborns during their earliest and most vulnerable period. The scale of this research offers healthcare professionals and parents-to-be with assurance in the vaccine’s established performance across varied populations and settings.
The results present a striking picture of the vaccine’s ability to protect. More than 4,500 babies were treated in hospital with RSV throughout the study period, with the great majority being infants whose mothers did not receive the vaccination. This marked difference highlights the vaccine’s critical role in preventing serious illness in newborns. The reduction in hospital admissions surpassing 80 per cent represents a major public health success, potentially preventing thousands of infants from experiencing the distressing and potentially serious symptoms associated with severe RSV infection. These findings support the importance of the vaccination programme introduced in the UK in 2024.
Research approach and coverage
The research analysed birth and hospitalisation records from England over a six-month period, capturing data on approximately 90 per cent of all births during this timeframe. By examining around 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to identify direct comparisons of RSV infection rates and hospital admissions. The sizeable sample and comprehensive nature of the data collection ensured that findings were statistically robust and reflective of the wider population, rather than isolated cases or limited subgroups.
The study specifically recorded hospital admissions for RSV among infants born to mothers who had received the vaccine at varying intervals before delivery. This allowed researchers to determine the shortest interval needed between vaccination and birth for optimal protection, as well as to determine whether protection stayed significant with briefer timeframes. The methodology assessed practical outcomes rather than experimental conditions, providing practical evidence of how the vaccine works when given across varied healthcare environments and patient circumstances throughout pregnancy’s final trimester.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Understanding RSV and its hazards
Respiratory syncytial virus, commonly referred to as RSV, is one of the leading causes of hospital admission in infants under one year of age across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their early months of life, with severity varying dramatically from mild cold-like symptoms to severe, life-threatening chest infections. Over 20,000 infants require intensive hospital care for RSV annually in the UK alone, placing considerable pressure on paediatric wards and neonatal units during peak seasons.
The infection causes deep inflammation in the lungs and airways, making it perilously hard for infected babies to feed and breathe properly. Parents commonly see their babies struggling visibly, their chests heaving as they try to pull adequate oxygen into their damaged lungs. Whilst most newborns improve through supportive care, a limited though important proportion perish from RSV-related complications annually, making vaccination as prevention a critical public health imperative for defending the youngest and most at-risk individuals in the population.
- RSV produces lung inflammation, causing serious respiratory problems in infants
- Nearly 50% of newborns contract the virus in their first few months of life
- Symptoms vary between minor cold-like symptoms to life-threatening chest infections requiring hospitalisation
- Over 20,000 UK infants require serious hospital care for RSV annually
- Few babies die from RSV complications annually in the UK
Adoption rates and specialist advice
Since the RSV vaccine programme began in 2024, health officials have emphasised the significance of pregnant women receiving their jab at the best time for maximum protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has emphasised that timing is crucial for ensuring newborns benefit from the maximum immunity from birth. Whilst the study demonstrates that vaccination at least four weeks before delivery provides approximately 85% protection, experts advise women to receive their vaccine as early as possible from 28 weeks of pregnancy forward to enhance the antibodies passed to their babies through the placenta.
The messaging from health authorities remains clear: pregnant women should make a priority of vaccination during their final three months, even if circumstances mean they cannot receive the jab at the ideal window. Dr Watson has reassured pregnant women that protection remains still achievable with reduced timeframes between immunisation and delivery, including even a two-week gap for those giving birth ahead of schedule. This flexible approach recognises the realities of pregnancy and childbirth whilst maintaining strong safeguarding for at-risk infants during their most critical early months when RSV represents the highest danger of severe infection.
Regional differences in vaccine uptake
Whilst the RSV vaccine programme has been implemented across England, uptake rates and implementation timelines have differed across different regions and NHS trusts. Certain regions have achieved greater immunisation rates among qualifying expectant mothers, whilst others continue working to boost understanding and availability of the jab. These regional differences reflect variations in medical facilities, engagement approaches, and community involvement initiatives, though the national data demonstrates consistently strong protection regardless of geographical location.
- NHS trusts rolling out varied communication campaigns to reach expectant mothers
- Inconsistencies across regions in vaccination coverage levels in different parts of England necessitate strategic intervention
- Community health services modifying schemes to align with local requirements and situations
Practical implications and parental perspectives
The vaccine’s remarkable effectiveness provides tangible benefits for families throughout the United Kingdom. With over 20,000 babies admitted to hospital annually due to RSV before the launch of this safeguarding intervention, the 80% drop in admissions represents thousands of infants protected against severe infection. Parents no longer face the distressing scenario of seeing their babies gasping for air or labour to feed, symptoms that mark critical RSV illness. The vaccine has markedly changed the picture of neonatal respiratory health, providing expectant mothers a preventative option to safeguard their most at-risk babies during those crucial first weeks.
For families like that of Malachi, whose severe RSV infection caused profound brain damage, the vaccine’s accessibility carries significant emotional significance. His mother’s advocacy for the jab emphasises the life-altering consequences that preventable illness can cause to young children and their families. Whilst Malachi’s experience predates the vaccine programme, his story resonates strongly with parents now provided with protection. The knowledge that such significant complications—hospitalisation, oxygen dependency, neurological damage—are now largely preventable has provided considerable reassurance to women in pregnancy navigating their final trimester, changing what was once an unavoidable seasonal threat into a controllable health concern.